Literature DB >> 11413293

Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses.

M B Oldstone1, H Lewicki, D Homann, C Nguyen, S Julien, J E Gairin.   

Abstract

Members of the Arenaviridae family have been isolated from mammalian hosts in disparate geographic locations, leading to their grouping as Old World types (i.e., lymphocytic choriomeningitis virus [LCMV], Lassa fever virus [LFV], Mopeia virus, and Mobala virus) and New World types (i.e., Junin, Machupo, Tacaribe, and Sabia viruses) (C. J. Peters, M. J. Buchmeier, P. E. Rollin, and T. G. Ksiazek, p. 1521-1551, in B. N. Fields, D. M. Knipe, and P. M. Howley [ed.], Fields virology, 3rd ed., 1996; P. J. Southern, p. 1505-1519, in B. N. Fields, D. M. Knipe, and P. M. Howley [ed.], Fields virology, 3rd ed., 1996). Several types in both groups-LFV, Junin, Machupo, and Sabia viruses-cause severe and often lethal human diseases. By sequence comparison, we noted that eight Old World and New World arenaviruses share several amino acids with the nucleoprotein (NP) that consists of amino acids (aa) 118 to 126 (NP 118-126) (RPQASGVYM) of LCMV that comprise the immunodominant cytotoxic T-lymphocyte (CTL) epitope for H-2(d) mice (32). This L(d)-restricted epitope constituted >97% of the total bulk CTLs produced in the specific antiviral or clonal responses of H-2(d) BALB mice. NP 118-126 of the Old World arenaviruses LFV, Mopeia virus, and LCMV and the New World arenavirus Sabia virus bound at high affinity to L(d). The primary H-2(d) CTL anti-LCMV response as well as that of a CTL clone responsive to LCMV NP 118-126 recognized target cells coated with NP 118-126 peptides derived from LCMV, LFV, and Mopeia virus but not Sabia virus, indicating that a common functional NP epitope exists among Old World arenaviruses. Use of site-specific amino acid exchanges in the NP CTL epitope among these arenaviruses identified amino acids involved in major histocompatibility complex binding and CTL recognition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413293      PMCID: PMC114349          DOI: 10.1128/JVI.75.14.6273-6278.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

Review 1.  Cytokine-mediated control of viral infections.

Authors:  L G Guidotti; F V Chisari
Journal:  Virology       Date:  2000-08-01       Impact factor: 3.616

2.  Defining parameters for successful immunocytotherapy of persistent viral infection.

Authors:  D P Berger; D Homann; M B Oldstone
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

3.  Virus-induced diabetes in a transgenic model: role of cross-reacting viruses and quantitation of effector T cells needed to cause disease.

Authors:  N Sevilla; D Homann; M von Herrath; F Rodriguez; S Harkins; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Transgenic mice expressing human HLA and CD8 molecules generate HLA-restricted measles virus cytotoxic T lymphocytes of the same specificity as humans with natural measles virus infection.

Authors:  A Tishon; D M LaFace; H Lewicki; R S van Binnendijk; A Osterhaus; M B Oldstone
Journal:  Virology       Date:  2000-09-30       Impact factor: 3.616

Review 5.  MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

6.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

7.  Effective vaccine for lassa fever.

Authors:  S P Fisher-Hoch; L Hutwagner; B Brown; J B McCormick
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes.

Authors:  J A Speir; K C Garcia; A Brunmark; M Degano; P A Peterson; L Teyton; I A Wilson
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

9.  Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice.

Authors:  K J Hasenkrug; D M Brooks; U Dittmer
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

Review 10.  The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.

Authors:  S A Kalams; B D Walker
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  7 in total

1.  A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.

Authors:  Peter J Bredenbeek; Richard Molenkamp; Willy J M Spaan; Vincent Deubel; Phillippe Marianneau; Maria S Salvato; Dmitry Moshkoff; Juan Zapata; Ilia Tikhonov; Jean Patterson; Ricardo Carrion; Anysha Ticer; Kathleen Brasky; Igor S Lukashevich
Journal:  Virology       Date:  2006-01-18       Impact factor: 3.616

2.  Identification of protective Lassa virus epitopes that are restricted by HLA-A2.

Authors:  Jason Botten; Jeff Alexander; Valerie Pasquetto; John Sidney; Polly Barrowman; Joey Ting; Bjoern Peters; Scott Southwood; Barbara Stewart; Maria P Rodriguez-Carreno; Bianca Mothe; J Lindsay Whitton; Alessandro Sette; Michael J Buchmeier
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Envelope exchange for the generation of live-attenuated arenavirus vaccines.

Authors:  Andreas Bergthaler; Nicolas U Gerber; Doron Merkler; Edit Horvath; Juan Carlos de la Torre; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2006-06-02       Impact factor: 6.823

Review 5.  Immune responses and Lassa virus infection.

Authors:  Marion Russier; Delphine Pannetier; Sylvain Baize
Journal:  Viruses       Date:  2012-11-05       Impact factor: 5.048

Review 6.  Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Authors:  Stephan Olschläger; Lukas Flatz
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

Review 7.  CD8 T cell responses to viral infections in sequence.

Authors:  Michael A Brehm; Liisa K Selin; Raymond M Welsh
Journal:  Cell Microbiol       Date:  2004-05       Impact factor: 3.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.